This study examines the effects of antihypertensive therapy on platelet cytosolic calcium [Ca2+](i) responses to low-density lipoprotein cholesterol (LDL) and vasopressin (AVP) in 15 patients (50-80 years) participating in the Hypertension Optimal Treatment International Study. All patients (diastolic blood pressure (DBP) ≥ 100 mm Hg and ≤ 115 mm Hg) were treated with the calcium antagonist felodipine (10 mg po) with or without addition of enalapril (up to 20 mg daily as needed) to lower diastolic pressures to < 85 mm Hg. This antihypertensive therapy lowered DBP (104 ± 0.8 to 78 ± 1.6 mm Hg, P < 0.0001), but had no effect on basal [Ca2+](i) or AVP-stimulated [Ca2+], responses. Basal platelet [Ca2+], following antihypertensive therapy (49 ± 3.4 ng/ml) were not different from those prior to therapy (52 ± 4.7 ng/ml). Additionally, [Ca2+], responses to AVP following therapy (554 ± 74 units) were not different from those prior to treatment (595 ± 49 units). Following antihypertensive therapy, [Ca2+], responses to 200 μg/ml of LDL were decreased fourfold (P < 0.05). These results suggest that anithypertensive therapy with a calcium channel blocker may potentially impact the atherogenic process by reducing the platelet [Ca2+](i) rise, and potentially the aggregatory response, to LDL.
|Original language||English (US)|
|Number of pages||4|
|Journal||Journal of Human Hypertension|
|State||Published - Mar 1996|
- Platelet cytosolic calcium
ASJC Scopus subject areas
- Internal Medicine